These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 2044221)
21. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Greipp PR; Lust JA Stem Cells; 1995 Aug; 13 Suppl 2():10-21. PubMed ID: 8520496 [TBL] [Abstract][Full Text] [Related]
22. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351 [TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin secretion by peripheral blood and bone marrow B cells in patients with multiple myeloma. Studies by the reverse haemolytic plaque assay. Dammacco F; Vacca A; Altomare E; Campobasso N Clin Exp Immunol; 1984 Sep; 57(3):743-51. PubMed ID: 6380841 [TBL] [Abstract][Full Text] [Related]
24. [Soluble interleukin 2 receptor (sIL-2R) in patients with esophageal carcinoma]. Duan ZF Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):17-9. PubMed ID: 8334935 [TBL] [Abstract][Full Text] [Related]
25. [Soluble interleukin-6 receptors in the serum in multiple myeloma]. Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823 [TBL] [Abstract][Full Text] [Related]
26. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399 [TBL] [Abstract][Full Text] [Related]
27. [Elevated soluble interleukin-2 receptor and interleukin-2 receptor positive cells in carcinomatous pleural effusions]. Kojiro N; Moriwaki Y; Ito M; Nishiki M; Shirasaka T; Kokubu T Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Jan; 28(1):100-4. PubMed ID: 2355670 [TBL] [Abstract][Full Text] [Related]
28. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity. Yosipovitch G; Shohat B; Bshara J; Wysenbeek A; Weinberger A Isr J Med Sci; 1995 Jun; 31(6):345-8. PubMed ID: 7607852 [TBL] [Abstract][Full Text] [Related]
29. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503 [TBL] [Abstract][Full Text] [Related]
30. Immunoregulatory proteins in bronchoalveolar lavage fluid. A comparative analysis of pigeon breeders' disease, sarcoidosis and idiopathic pulmonary fibrosis. Reynolds SP; Jones KP; Edwards JH; Davies BH Sarcoidosis; 1989 Sep; 6(2):125-34. PubMed ID: 2602684 [TBL] [Abstract][Full Text] [Related]
31. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117 [TBL] [Abstract][Full Text] [Related]
32. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Macciò A; Lai P; Santona MC; Pagliara L; Melis GB; Mantovani G Gynecol Oncol; 1998 Jun; 69(3):248-52. PubMed ID: 9648596 [TBL] [Abstract][Full Text] [Related]
34. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552 [TBL] [Abstract][Full Text] [Related]
35. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. Symons JA; Wood NC; Di Giovine FS; Duff GW J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665 [TBL] [Abstract][Full Text] [Related]
36. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104 [TBL] [Abstract][Full Text] [Related]
37. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms. Bodey B; Psenko V; Lipsey AL; Kaiser HE Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612 [TBL] [Abstract][Full Text] [Related]
38. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis. Simpson KJ; Jones AL; Forbes Howie A; Hayes PC Eur J Gastroenterol Hepatol; 1995 May; 7(5):455-60. PubMed ID: 7542148 [TBL] [Abstract][Full Text] [Related]
39. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Wierzbowska A; Urbańska-Ryś H; Robak T Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412 [TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 receptor expression and saturation on the bone marrow cells of patients with multiple myeloma. Brown RD; Gorenc B; Gibson J; Joshua D Leukemia; 1993 Feb; 7(2):221-5. PubMed ID: 8426476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]